Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Johnson and Johnson
Dow
Medtronic
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Patent: 10,350,178

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,350,178
Title:Methods and compositions for treatment of demyelinating diseases
Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
Inventor(s): Blitzer; Jeremy (San Francisco, CA), McKearn; John (St. Louis, MO)
Assignee: Pathologica LLC (San Francisco, CA)
Application Number:16/109,824
Patent Claims:see list of patent claims

Details for Patent 10,350,178

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Pathologica LLC (San Francisco, CA) 2033-01-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Harvard Business School
AstraZeneca
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.